chrisvoncsefalvay/vaers-outcomes huggingface dataset:
felt tingling in her feet and hands; fatigue; nausea; headache; This spontaneous case was reported by a consumer and describes the occurrence of PARAESTHESIA (felt tingling in her feet and hands), FATIGUE (fatigue), NAUSEA (nausea) and HEADACHE (headache) in a 69-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 006B21A) for COVID-19 vaccination.     Concurrent medical conditions included Contrast media allergy (severe allergic reaction to contrast dye). Concomitant products included HCTZ for an unknown indication.    On 20-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 20-Mar-2021, the patient experienced PARAESTHESIA (felt tingling in her feet and hands), FATIGUE (fatigue), NAUSEA (nausea) and HEADACHE (headache). The patient was treated with WATER at an unspecified dose and frequency; DIAZEPAM at an unspecified dose and frequency and PARACETAMOL (TYLENOL) at an unspecified dose and frequency. At the time of the report, PARAESTHESIA (felt tingling in her feet and hands), FATIGUE (fatigue), NAUSEA (nausea) and HEADACHE (headache) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 20-Mar-2021, Blood pressure measurement: >200 (Inconclusive) BP was >200. On 20-Mar-2021, Heart rate: 115 (Inconclusive) HR was 115.     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Treatment details included  fluids, OJ.
I felt like my heart was racing; My breathing was off; I was feeling a pain in the left side of my chest under my breast and under my ribs that would come and go; This is a spontaneous report from a non-contactable other healthcare professional, the patient. A 40-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0178) via an unspecified route of administration in the left arm on an unknown date (at the age of 40-years-old) as a single dose for COVID-19 immunisation. Medical history included known allergies to possibly sulfa drugs. Prior to vaccination, it was unknown whether the patient was diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient did not receive any concomitant medications. The patient previously took tetracycline (MANUFACTURER UNKNOWN) and doxycycline (MANUFACTURER UNKNOWN); both taken for unknown indications and experienced drug allergy. On an unknown date, the patient felt like her heart was racing, her breathing was off, and she was feeling a pain in the left side of her chest under her breast and under her ribs that would come and go on the first night and into the second day. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. The clinical outcome of the events she felt like her heart was racing, her breathing was off, and she was feeling a pain in the left side of her chest under her breast and under her ribs that would come and go was unknown at the time of this report.  No follow-up attempts are possible. No further information is expected.
After three days, the arm from shoulder to elbow became swollen, hard, hot to the touch, and red.
I broke out into hives and couldn?t stop itching my torso from 600pm to midnight. I took 2 Benadryl at 700pm and still had horrible itching. At 1000pm I took 1 more Benadryl and the itching subsided at midnight. This occurred 6 days after my vaccination.
Information has been received from a 50 year old male patient enrolled in market research, concerning himself. Patient medical history and current condition was not reported. On an unknown date, the patient was vaccinated with a dose of PNEUMOVAX 23 (dose, route, frequency, lot # and expiration date were not reported). Other co-suspects and concomitant medication was not reported. It was reported that the patient got sick the last he got PNEUMOVAX 23 (dates unspecified). The action taken of PNEUMOVAX 23 and the outcome of the event was unknown. Causality assessment was not provided by the reporter. Additional information has been requested.
Arm tingling; Arm numb/hand numb; Arm throbbing; This spontaneous case was reported by a consumer and describes the occurrence of PARAESTHESIA (Arm tingling), HYPOAESTHESIA (Arm numb/hand numb) and PAIN (Arm throbbing) in a 55-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 037T21A) for COVID-19 vaccination.     No Medical History information was reported.    On 20-Sep-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced PARAESTHESIA (Arm tingling), HYPOAESTHESIA (Arm numb/hand numb) and PAIN (Arm throbbing). At the time of the report, PARAESTHESIA (Arm tingling), HYPOAESTHESIA (Arm numb/hand numb) and PAIN (Arm throbbing) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       Concomitant medications were not reported. No treatment information was provided.
vomiting 2x, so weak he had to crawl to the toilet, every part of the body burns and aches, headache so bad it feels like a bullet to the head, awake all night with insomnia, can barely walk without falling down
Pain in left shoulder starting a couple hours after the dose.  Patient has been in constant dull pain subjectively at a 5 on the pain scale per patient on 02/11/2022.  Massaging the arm makes it feel better for about an hour then the pain returns.
hypotensive 90/54 approx 7 minutes p/shot; loss of bladder control, tone, eyes rolled back;
Pt recvd vax & returned to ER c/o redness, induration & warmth @ the inject site;
01/01/22 presents to EC ED for "dizziness". PMHx of "DM, GERD"
This spontaneous report as received from a health care worker refers to unspecified number of patients of unknown age. It was reported that the ROTATEQ of unknown dose, have undergone a second temperature excursion dated 2-JUL-2014 and have been administered post initial excursion reported as 16-JAN-2014. Excursion supported. It was reported that no adverse events and no concerns are reported by any patients. ROTATEQ have been administered since date of last excursion of 27-JAN-2014 is with Lot number reported as J008740 and expiry date reported as 22-MAR-2018. This is one of several reports from the same source: different patients same reporter. Additional information has been requested.
No immediate reaction. Starting around 48 hours after vaccination (Saturday 6/5), client noted swelling, redness and pain at site of injection that spread to left axillary and breast area. Swelling was significant enough that mother described it as "he looked like he had a breast". They sought medical attention on Monday 6/7 at pediatrician's office. Swelling had decreased but was still present. Pediatrician advised ibuprofen. Symptoms resolved within 5 days post vaccination.
Systemic: Flushed / Sweating-Mild, Systemic: Nausea-Mild, Systemic: Shakiness-Mild, Systemic: Vomiting-Mild, Additional Details: Patient became nauseous and pale several minutes after inject.  She was stated she was nervous about injections and felt a little lightheaded and did vomit one time.  She returned to normal within 10 minutes and was monitored the whole time.
This spontaneous report as received from a healthcare worker refers to a 13 years old male patient with no pertinent medical history and no drug reactions or allergies. The patient was vaccinated with the first dose of GARDASIL on 06-JUN-2012 in the immunization series. No concomitant medications were reported. On 06-JUN-2012 while the patient was standing at the front counter of the practice, just before leaving, he collapsed and exhibited jerky movement. No treatment information was given for the adverse events. No lab diagnostics studies performed. The patient examined by the physician, revived on his own and left the practice a short while later. Additional information has been requested.
Initial information and follow up has been received from a physician and 35 year old female who on 08-FEB-2008, was vaccinated intramuscularly in error (the patient was suppose to receive the 2nd dose of hepatitis B) with her second dose of GARDASIL (lot# not reported). Concomitant therapy, in January 2008, included hepatitis B virus vaccine (unspecified manufacturer), for the treatment of prophylaxis (duration and dose not reported). After the first GARDASIL dose, the patient had pain in the opposite arm that lasted 2-3 months (recovered in June 2008). In March or May 2008, the patient went to the doctors office to receive another hepatitis B vaccine and was given another dose of GARDASIL (lot# not reported). The patient does not know if she will complete the GARDASIL or hepatitis B vaccine series. Additional information has been requested.
Headache, NauseaVomiting, Fatigue, chills, injection site pain and swelling, joint pain Narrative:
Missed her second dose/More than 35 days have passed; tested positive for COVID; was sick; This spontaneous case was reported by a pharmacist and describes the occurrence of ILLNESS (was sick), PRODUCT DOSE OMISSION ISSUE (Missed her second dose/More than 35 days have passed) and COVID-19 (tested positive for COVID) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 24-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 30-Jan-2021, the patient experienced ILLNESS (was sick) and COVID-19 (tested positive for COVID). On an unknown date, the patient experienced PRODUCT DOSE OMISSION ISSUE (Missed her second dose/More than 35 days have passed). At the time of the report, ILLNESS (was sick) and COVID-19 (tested positive for COVID) outcome was unknown and PRODUCT DOSE OMISSION ISSUE (Missed her second dose/More than 35 days have passed) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No concomitant medications reported. No treatment information was provided.
Chest pains and shortness of breath started within an hour from vaccination. 3 hours after shot dizziness and chills began.  The following day symptoms progressed and lasted all day. Severe dizziness, blurred vision, muscle aches, headaches, chills , shortness of breath, chest pains, sore throat, cough, fatigue, fever(up to 102.5).
Shoulder pain: After his flu shot, his arm hurt right away and hasn't felt the same since. He went home and started getting sore that night, couldn't move his shoulder like normal. Since then, it just hasn't gotten better. Has been persistent every day. Patient has been getting Physical therapy, oral steroids and a steroid injection.
Inappropriate schedule of vaccine administered; This spontaneous case was reported by a consumer and describes the occurrence of INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Inappropriate schedule of vaccine administered) in a 66-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 0061321A) for COVID-19 vaccination.     No Medical History information was reported.    On 17-Apr-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 17-Apr-2021, the patient experienced INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Inappropriate schedule of vaccine administered). The patient was treated with PARACETAMOL (TYLENOL [PARACETAMOL]) for Pain, at an unspecified dose and frequency and NAPROXEN SODIUM (ALEVE) for Pain, at an unspecified dose and frequency. On 17-Apr-2021, INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Inappropriate schedule of vaccine administered) had resolved.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): In September 2021, Magnetic resonance imaging: unknown (Inconclusive) A definite cause or diagnosis was not provided.         Symptoms: It was reported that the patient had not experienced any problems with her right arm where she received her 2nd dose of vaccine and no other adverse events were reported.  Lab test includes: other tests were performed. Treatment medication includes: Other prescribed pain medicine  No concomitant medications were reported   This case was linked to MOD-2021-408546 (Patient Link).
Initial information received on 01-Nov-2018 regarding an unsolicited valid non-serious case received from a pharmacist. This case is linked to case 2018SA304598 (same reporter). This case involves a 31 patients (gender was not reported) who developed a boil at the injection site, while he/she received vaccine FLUZONE QUADRIVALENT. The patients' past medical history, medical treatment(s), vaccination(s) and family history were not provided. Concomitant medication were not reported. On an unknown date, the patients received a 0.5 ml dose of suspect INFLUENZA QUADRIVAL A-B VACCINE (lot number: UI998AE and expiry date: 30-Jun-2019) via intramuscular route in unknown administration site. On an unknown date, the patients developed a non-serious boil at the injection site following the administration of INFLUENZA QUADRIVAL A-B VACCINE. It was reported that one patient had the boil cultured and there were no bacterial growth. (Other relevant tests included No lab data). Final diagnosis was developed a boil at the injection site. It was not reported if the patient received a corrective treatment. The patient outcome is reported as Unknown for developed a boil at the injection site. Follow up information was received from a pharmacist on 05-Nov-2018. Vaccination details of the suspect product was updated. List of documents held by sender: none.
This spontaneous report as received from a other health professional refers to a 41 year old patient. On 21-MAY-2014 the patient was vaccinated with MMR II lot # J006955. No other concomitant medications were reported. On 21-MAY-2014, 1 day after onset of therapy the patient experienced patients received MMR II post not supported excursion (doses stored at 17C for 21.5 hours) and Inappropriate schedule of vaccine administered. The outcome of patients received MMR II post not supported excursion (doses stored at 17C for 21.5 hours) and Inappropriate schedule of vaccine administered is unknown. The reporter stated that patients who received MMR II have not expressed any adverse events. The reporter considered patients received MMR II post not supported excursion (doses stored at 17C for 21.5 hours), Inappropriate schedule of vaccine administered and not expressed any adverse events to be not related to MMR II. This case is linked to same reporter linked cases # 1406USA004912 and 1405USA012040. Additional information has been requested.
60 hours post injection developed erythematous patch on  Left lateral thigh, no fever.
Increased confusion about six hours after vaccine lasting about 12-18 hours. Resolved spontaneously
EE reports, started to be nauseous overnight, 1/12 into 1/13.   1/13 10 am, chest heaviness, SOB, anxiety, unable to function at work  1/13/2021, to Urgent Care, prescribed zofran for nausea.  Was asked to contact her PCP regarding her HR 130,  EE was on buprion and abruptly stopped taking it for 2 weeks without PCP recommendation, "I thought I didn't need it anymore".  EE reported to OHN on 1/13, she restarted the med and took her first dose on 1/12 and her second one on 1/13.   Covid results negative
Tongue numbness on right side. Mouth feels scalded then moved to feeling like a Novocain  injection, only one one side.  Numbness has moved to middle/back of tongue. Red bumps on tongue.
RASH ON SITE OF SHOT RX FOR BENADRYL 25MG 1 TAB EVERY 6 HRS
Information regarding PREVNAR was received from a healthcare professional regarding a patient who experienced low antibody titers. The patient received a dose on an unspecified date. The patient experienced low antibody titers. The patient's outcome is unknown. No additional information was available at the time of this report.
Muscle aches after 1st dose; Headache after 1st dose; Fatigue after 1st dose; This spontaneous case was reported by a consumer and describes the occurrence of MYALGIA (Muscle aches after 1st dose), HEADACHE (Headache after 1st dose) and FATIGUE (Fatigue after 1st dose) in a 69-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 025A21A) for COVID-19 vaccination.     No Medical History information was reported.    On 27-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 28-Feb-2021, the patient experienced MYALGIA (Muscle aches after 1st dose), HEADACHE (Headache after 1st dose) and FATIGUE (Fatigue after 1st dose). On 01-Mar-2021, MYALGIA (Muscle aches after 1st dose), HEADACHE (Headache after 1st dose) and FATIGUE (Fatigue after 1st dose) had resolved.        mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosing remained unchanged.       The  concomitant medications on use were not provided. No treatment information was provided.  Patient was not under any regular or concomitant medication and stated she had no allergies history.   This case was linked to MOD-2022-468796, MOD-2022-468797 (Patient Link).
This spontaneous report was received from a medical assistant regarding a patient of unknown age and gender. Information on the concurrent conditions, pertinent medical history and drug allergies of the patient were not reported. On an unknown date in March 2015, the patient was vaccinated with first dose of GARDASIL 9 (lot, expiry date, dose units, route and anatomical location were not specified). On 21-DEC-2015 the patient was vaccinated with second dose of GARDASIL 9 (lot, expiry date, dose units. route and anatomical location were not specified). No adverse effects were reported. There was no Product Quality Complaint (PQC) involved. Additional information has been requested.
This is a spontaneous report from Pfizer-sponsored program.  This contactable consumer reported same event for both her son and herself. This is the report for her son. The consumer (patient's mother) reported that a male patient of an unspecified age received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE), dose 1 via an unspecified route of administration on 20Apr2021 (Batch/Lot number was not reported) as single dose for covid-19 immunisation.  The patient medical history and concomitant medications were not reported.  The patient experienced eye pain on 21Apr2021. The outcome of event was unknown.  No follow-up attempts are Possible. Information about lot/batch number cannot be obtained.; Sender's Comments: Linked Report(s)
Recent COVID + diagnosis/Covid exposure; Recent COVID + diagnosis/Covid exposure; This is a spontaneous report from contactable nurses. This nurse reported same events for 4 patients. This is 4th of 4 reports. A patient of unspecified age and gender received first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, Solution for injection), via an unspecified route of administration on 22Dec2020 at single dose for covid-19 immunisation. The patient medical history and concomitant medications were not reported. The reporter stated that 4 employees that had been vaccinated with a 1st dose had to defer to 02Feb2021 due to recent COVID + diagnosis/Covid exposure. The outcome of events was unknown.  Information on the lot/batch number has been requested.; Sender's Comments: Based on available information, a possible contributory role of BNT162B2 cannot be completely excluded for reported events.,Linked Report(s) : US-PFIZER INC-2021035084 same reporter, product and adverse events in different patients
This spontaneous report as received from a healthcare worker refers to multiple unspecified patients of unknown age and gender. The patients' pertinent medical history, drug reactions/allergies and concomitant therapies were not reported. On unknown dates, the patients were vaccinated with improperly stored doses of GARDASIL (dose and route were not reported, lot # K023432 with expiration date: 18-JUN-2016). The patients received the vaccinations between 06-NOV-2015 and 10-NOV-2015. No adverse effects were reported. This is one of several reports received from the same reporter. Additional information has been requested.
Skin on left front under breast and left side of back aligning with the area in front is sore - there is no rash, no spots - just a sensitivity in a small area both front and back
Started having a sore throat and drippy nose. Took a home COVID-19 test and was positive. Called Telehealth and was prescribed Paxlovid. Feeling better now. Breakthrough case.
Metallic taste in mouth - like having pennies on my tongue. Occasional Tingle/numbness of lips
Family noted right upper eyelid swelling on waking the day after this vaccine. Family also notes this has happened after every vaccination, but resolves by the end of the day.
Recieved 2nd dose of COVID-19 vaccine  at 7:56am. Walked back to clinic . Around 0900 started feeling throat tightening and throat itching, reports bilat hand felt numb. Walked back to vaccine clinic with co-worker . Reports ALG to Amoxicillin=rash/throat swelling. Employee A/O x 4, color pink, no difficulty breathing, tongue not swollen, but anxious. Moved to Employee Health Services (EHS) for observation are via w/c. Given 50 mg of po Benadryl. VS and pulse ox  monitored. V/S and O2sat remained with normal limits. At 11:00am, Employee reported the her throat swelling and itchiness had resolved.  D/C home, escorted by  husband (HCW). Follow-up call made by health care provider at 17:36pm, employee reported her symptoms had resolved and she took a long nap.
pt recvd vax 19APR94 & 25APR94 pt had temp of 103 & rash over entire body & extremities, small bumps, flesh colored; temp & rash gone in less than 24 hrs; seen by Md 28APR94 dx hives, onset 28APR94; seen in ER for same 29APR94;
Tense sore chest; Tense sore chest/elbows/knees/shoulders; This is a spontaneous report from a contactable consumer or other non healthcare professional. A 49 year old female patient received bnt162b2 (BNT162B2), dose 2 via an unspecified route of administration, administered in Arm Left on 24May2021 13:15 (Batch/Lot Number: EW0187) as DOSE 2, SINGLE for covid-19 immunisation. The patient medical history was not reported. Concomitant medication(s) included acetylsalicylic acid (ASPIRIN (E.C.)) taken for an unspecified indication from an unspecified start date and ongoing; cetirizine hydrochloride (ZYRTEC ALLERGY) taken for an unspecified indication from an unspecified start date and ongoing; caffeine, paracetamol (EXCEDRIN [CAFFEINE;PARACETAMOL]) taken for an unspecified indication from an unspecified start date and ongoing; diphenhydramine hydrochloride, paracetamol (TYLENOL PM) taken for an unspecified indication from an unspecified start date and ongoing. The patient experienced tense sore chest on 05Jun2021 with outcome of unknown , tense sore chest/elbows/knees/shoulders on 05Jun2021 with outcome of unknown. The patient underwent lab tests and procedures which included blood test, electrocardiogram, gynaecological examination and ultrasound pelvis with unknown results.  Follow-Up (10Aug2021): Follow-up attempts are completed. No further information is expected.